Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2008 Apr;17(4):555-64.
doi: 10.1517/13543784.17.4.555.

ACAM2000: a newly licensed cell culture-based live vaccinia smallpox vaccine

Richard N Greenberg  1 , Jeffrey S Kennedy
Affiliations
Review

ACAM2000: a newly licensed cell culture-based live vaccinia smallpox vaccine

Richard N Greenberg et al. Expert Opin Investig Drugs. 2008 Apr.

Abstract

Background: Due to concern over i) expiration of currently available calf-lymph vaccine (Dryvax); ii) calf lymph as a vaccine (bovine spongiform encephalopathy [BSE], other possible contaminations and animal welfare); and iii) use of variola as a weapon for bioterrorism, a new and safer vaccinia-based smallpox vaccine derived from new cell culture-based technology was proposed. Federally funded work by Acambis, Inc. resulted in FDA approval for ACAM2000 in August 2007.

Objectives: This paper describes the development from conception to FDA approval of the new vaccinia cell cultured-based smallpox vaccine ACAM2000.

Methods: Data were compiled from available public reports.

Results/conclusions: The studies with ACAM2000 indicate that it closely matches the safety of Dryvax in both non-clinical and clinical trials. ACAM2000 met two of the four primary surrogate efficacy end point criteria established for the Phase III clinical trials. Concern over the incidence of myopericarditis with ACAM2000 and Dryvax exists. So far the cardiac events seem to be self-limited. There are no pediatric safety data for ACAM2000. Overall, clinical trial results were sufficient to convince the FDA that ACAM2000 is a suitable replacement for Dryvax in the event of bioterrorism involving variola (smallpox).

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Rock MT, Yoder SM, Talbot TR, et al. Cellular immune responses to diluted and undiluted aventis pasteur smallpox vaccine. J Infect Dis 2006;194:435-43 - PubMed
    1. LeDuc JW, Becher J. Current status of smallpox vaccine. Emerg Infect Dis 1999;5:593-4 - PMC - PubMed
    1. Weltzin R, Liu J, Pugachev KV, et al. Clonal vaccinia virus grown in cell culture as a new smallpox vaccine. Nat Med 2003;9:1125-30 - PubMed

    2. This definitive paper on ACAM1000 describes the preclinical selection of the vaccinia clone designated ACAM1000 and a clinical trial comparing ACAM1000 with Dryvax.

    1. Poland GA, Neff JM. Smallpox vaccine: problems and prospects. Immunol Allergy Clin North Am 2003;23:731-43 - PubMed
    1. Slifka MK. The future of smallpox vaccination: is MVA the key? Med Immunol (London) 2005;4:2 - PMC - PubMed